Drug Company Will Buy Up to $700 Million in BNB After Coin Hits All-Time High
Windtree Therapeutics announced its intention to purchase up to $700 million worth of BNB, the fifth-largest cryptocurrency, to boost its balance sheet. Following a new all-time high for BNB at $808, the Nasdaq-listed company plans to raise $520 million for these acquisitions through an equity line of credit and a stock-purchase agreement. Windtree aims to leverage this investment strategy similar to recent moves by other publicly traded companies, such as Strategy, that have adopted crypto assets like BNB to enhance their stock valuations. CEO Jed Latkin emphasized the importance of this funding strategy pending stockholder approval. Despite a slight dip in stock price recently, Windtree's shares have increased by 162% over the past month. The firm has also partnered with Kraken to facilitate custody of the BNB acquired. This strategy aligns with a growing trend of companies integrating digital assets into their financial frameworks, contributing to their overall market presence.
Source đź”—